EnFr
When women and adolescent girls have access to a variety of contraceptives, they are more likely to find and use a method that meets their needs and decide whether and when they want to become pregnant as well as how many children they want to have. And the addition of a new contraceptive method to the mix, or expanding geographic access to existing methods, can attract new contraceptive users and increase contraceptive prevalence. Data shows that when one additional contraceptive method is offered to at least half of a population, total contraceptive use can increase by four to eight percent.
Subcutaneous DMPA (DMPA-SC)* is an innovative injectable that can open up contraceptive access and choice to women and adolescent girls at the last mile and promote their autonomy.
This resource library has been developed to provide comprehensive information on DMPA-SC evidence, country introduction experiences, service delivery and advocacy tools, and more for global- and country-level family planning implementers and decision-makers. We welcome your suggestions—if you have resources to submit, please contact us at FPoptions@path.org.
This site is hosted by the Advancing Injectable Markets for Sustainability (AIMS) project led by PATH in partnership with the Africa Resource Centre, Health Systems Insight, Metrics for Management, and Solina Centre for International Development and Research. The AIMS project is dedicated to improving women’s choice and enduring access to injectable contraception. AIMS is creating a sustainable market for DMPA-SC and self-injection (SI), ensuring balanced supply and demand with robust public- and private-sector access to contraceptive injectables for women living in low- and middle-income countries. This resource library was developed to help further those efforts.
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate. Brand name: Sayana Press.
Photo: PATH/Gabe Bienczycki